drugset
Drugs / Olaptesed pegol
last change Jan 2026 re-read 2 minutes ago

Olaptesed pegol

also known as NOX-A12 · NOX-A12 FREE ACID

Oligonucleotide (other) targets CXCL12 via inhibition

Developed for
malignant pancreatic neoplasm · chronic lymphocytic leukemia/small lymphocytic lymphoma · colorectal cancer · glioblastoma · plasma cell myeloma
Investigated by
TME Pharma AG · Merck Sharp & Dohme LLC · German Federal Ministry of Education and Research

Trials 7 · a red edge is where a trial was stopped

today NCT04901741 · Ph 2 NCT04121455 · Ph 1/2 NCT03168139 · Ph 1/2 NCT01521533 · Ph 2 NCT01486797 · Ph 2 NCT01194934 · Ph 1 NCT00976378 · Ph 1
20102011201220132014201520162017201820192020202120222023202420252026202720282029
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 12 trials
Phase 1 NCT01194934 Aug 2010 → Jan 2011 disease related to hematopoietic stem cell transplant TME Pharma AG Completed No outcome recorded
Phase 1 NCT00976378 Oct 2009 → May 2010 disease related to hematopoietic stem cell transplant TME Pharma AG Completed No outcome recorded
Phase 1/22 trials
Phase 1/2 NCT04121455 Sep 2019 → Dec 2028 expected glioblastoma TME Pharma AG Active not recruiting No outcome recorded
Phase 1/2 NCT03168139 Apr 2017 → Mar 2020 colorectal cancer, malignant pancreatic neoplasm TME Pharma AG Completed No outcome recorded
Phase 23 trials
Phase 2 NCT04901741 Jan 2026 → Mar 2028 expected malignant pancreatic neoplasm TME Pharma AG Not yet recruiting No outcome recorded
Phase 2 NCT01521533 Mar 2012 → Sep 2014 plasma cell myeloma TME Pharma AG Completed No outcome recorded
Phase 2 NCT01486797 Mar 2012 → Nov 2014 chronic lymphocytic leukemia/small lymphocytic lymphoma TME Pharma AG Completed No outcome recorded

Evidence & citations 7 cited values

Every value below carries the sentence it was read from. 9 sources stand behind the page.

FieldValueCited text
Known as Olaptesed pegol ClinicalTrials.gov intervention name — accepted as the source's own label NCT04901741 ↗
2

NCT04121455 ↗

NCT03168139 ↗
Known as NOX-A12 ClinicalTrials.gov intervention name — accepted as the source's own label NCT01521533 ↗
3

NCT01486797 ↗

NCT00976378 ↗

NCT01194934 ↗
Known as NOX-A12 FREE ACID ChEMBL registry synonym — accepted as the source's own label CHEMBL4594485 ↗
Action Inhibit “NOX-A12 is a specific CXCL12 antagonist” NCT01521533 ↗
Modality Oligonucleotide (other) “Olaptesed pegol (NOX-A12) is a pegylated structured L-oligoribonucleotide” PMID 31097627 ↗ May 2019
Route Intravenous “administered by single intravenous (IV) doses” NCT00976378 ↗
Target CXCL12 “binds and neutralizes CXCL12” PMID 31097627 ↗ May 2019